Synthetic 15-amino acid peptide derived from a gastric protein, researched for tissue repair, gut healing, tendon recovery, and anti-inflammatory effects.
Last Updated: May 2026
BPC-157 (Body Protective Compound-157) is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of body protection compound (BPC) found in human gastric juice. It is one of the most-researched peptides in the tissue repair and gut healing space, with an extensive preclinical research base developed predominantly by Predrag Sikirić's group at the University of Zagreb. Important regulatory update: BPC-157 was removed from the FDA's Category 2 bulk substances list on April 22, 2026 and is scheduled for Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026, with the FDA specifically evaluating its use for ulcerative colitis. This is the most advanced regulatory pathway for any non-FDA-approved peptide in the Peptigrity catalog.
BPC-157 is a synthetic 15-amino-acid pentadecapeptide derived from a partial sequence of a body protection compound originally identified in human gastric juice, proposed to act through multiple mechanisms: VEGF and growth hormone receptor upregulation, nitric oxide pathway modulation, GHRH receptor effects, and angiogenesis stimulation. The compound's tissue-protective and tissue-repair effects appear to be multi-pathway rather than single-receptor, with the Sikirić group's extensive research characterizing effects across virtually every organ system. Evidence level: Preclinical extensive (multiple organ systems, tissue repair, gut healing); limited human clinical research; FDA PCAC review July 2026 for ulcerative colitis.
Preclinical studies have demonstrated effects on tendon and ligament healing, gut inflammation reduction, ulcer healing, vascular protection, and broad tissue-repair mechanisms across rodent and other animal models. The Sikirić group has produced over 200 publications characterizing BPC-157 effects. Human clinical evidence is more limited than the preclinical base, with the absence of large Phase 2/3 RCTs being a notable gap. The FDA's July 2026 PCAC review will evaluate BPC-157 specifically for ulcerative colitis, the most clinically-relevant proposed indication. Evidence level: Preclinical extensive (200+ Sikirić publications across organ systems); human clinical limited; ulcerative colitis FDA review pending July 2026.
BPC-157 has the largest preclinical research base of any tissue-repair peptide in the Peptigrity catalog, and the most advanced FDA regulatory pathway among non-approved compounds — but the underlying human clinical evidence base remains less developed than the preclinical research suggests.
| Compound | Mechanism | Preclinical base | Human evidence | FDA pathway |
|---|---|---|---|---|
| BPC-157 | Multi-pathway tissue protection | Extensive (Sikirić, 200+ publications) | Limited | PCAC July 2026 (UC) |
| TB-500 | Thymosin Beta-4 fragment | Extensive | Limited | PCAC July 2026 (wound healing) |
| Follistatin | Myostatin inhibition | Moderate | Limited | None |
Side effects in available preclinical safety data and community-reported research use are generally mild — injection-site reactions are the most common report. The Sikirić group has emphasized a favorable preclinical safety profile across animal studies. Long-term safety in humans at sustained research-use dosing is not characterized at Western RCT standards. Theoretical concerns about angiogenesis effects (relevant for cancer biology) have been raised but not clinically substantiated. Evidence level: Preclinical safety extensive; human long-term unestablished; theoretical angiogenesis concerns unaddressed at human standards.
BPC-157 is not approved for any medical indication anywhere in the world as of May 2026. On April 22, 2026, BPC-157 was removed from the FDA's Category 2 bulk substances list. The Pharmacy Compounding Advisory Committee will review BPC-157 on July 23, 2026 specifically for the proposed use in ulcerative colitis. This is the most advanced regulatory pathway among non-FDA-approved peptides on Peptigrity, though removal from Category 2 does not authorize compounding pending PCAC determination. Current status in FDA peptide regulation 2025–2026 timeline.
BPC-157 is among the highest-volume peptides in research-grade markets, with substantial quality variance and occasional mislabeling — and the 15-amino-acid length makes synthesis quality control more important than for shorter peptides. Independent HPLC purity testing and mass spectrometry identity confirmation are essential. Some vendors sell BPC-157 acetate versus BPC-157 free base without clear labeling — the PCAC review specifically addresses both forms. Guidance in how-to-test-peptides hub.
Peptigrity purchases BPC-157 vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.
BPC-157 is researched extensively for tissue repair, gut healing, tendon and ligament recovery, ulcer healing, and broad tissue-protective effects across multiple organ systems. The preclinical base is substantial (200+ publications); human clinical evidence is more limited. The FDA's July 2026 PCAC review will evaluate the proposed ulcerative colitis use specifically.
BPC-157 is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption. The April 22, 2026 Category 2 removal and July 23, 2026 PCAC review represent the most advanced regulatory pathway for any non-FDA-approved peptide on Peptigrity. Country breakdown in peptide legal status guide.
The Pharmacy Compounding Advisory Committee will review BPC-157 on July 23, 2026, evaluating its proposed use for ulcerative colitis. The PCAC will make a recommendation to the FDA on whether BPC-157 should be added to the 503A bulks list. Public comments to the docket (FDA-2025-N-6895) were accepted through July 9, 2026. Track developments in FDA peptide regulation 2025–2026 timeline.
The theoretical angiogenesis-related concern (BPC-157's vascular effects could theoretically support tumor angiogenesis) has been raised in mechanism discussions but has not been clinically substantiated in available data. Long-term human surveillance has not been conducted at scale. Anyone with active cancer or cancer history should consult a licensed physician before considering BPC-157.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Some vendors don't clearly distinguish BPC-157 acetate versus BPC-157 free base — verify which form is being sold. COA interpretation in red flags in peptide certificates of analysis.
No. BPC-157 is not approved for human consumption and Peptigrity is an independent review platform, not a medical authority. Research-use dosing in community protocols varies widely by indication. Anyone considering use should consult a licensed physician — particularly given the July 2026 FDA review which may change the regulatory landscape.
BPC-157 is not specifically listed on the WADA Prohibited List as of May 2026 but related growth-factor-pathway compounds receive scrutiny. Detection methods for BPC-157 are evolving. For drug-testing context, see do peptides show up on drug tests.
This section is for educational and informational purposes only and does not constitute medical advice. BPC-157 is not approved by the FDA or any major Western regulator for human use, though it was removed from Category 2 of the FDA 503A bulk substances list in April 2026 and is scheduled for PCAC review on July 23, 2026 for the proposed use in ulcerative colitis. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.